At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).

Protalix BioTherapeutics reported Q2 2023 revenues of $35.08 million, a 300.72% YoY increase, beating Wall Street estimates. The US FDA approved PLX's Elfabrio for the treatment of Fabry disease in ...

Protalix received FDA and EU approval for Elfabrio. This puts the company on track for profitability as early as 2023. With a reasonable valuation and strong growth, I see a significant potential ...

The share price of Protalix BioTherapeutics (NYSEMKT:PLX) is off more than 43% in pre-market trading on Wednesday morning after the Israeli biopharma got word that the U.S. Food and Drug ...

Protalix BioTherapeutics, Inc PLX was a big mover last session, as the company saw its shares rise 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal ...

SPARTA, N.J., May 18, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically ...

While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get ...